Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Harrow Health, Inc.
HROW
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.6B
$42.74
▼ -0.60%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$28.54 - $54.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 40.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized expertise in ophthalmology with established ImprimisRx compounding platform
- Diversified revenue model combining core operations with high-growth equity investments
- Royalty rights providing passive income streams from multiple clinical-stage drug candidates
- Strategic positioning in high-demand therapeutic areas including ocular surface diseases and sedation
- Established relationships with eye care professionals and healthcare providers
Bear Case
2 risks
- Low volatility (beta 0.3).
- High premium - requires strong execution
Growth
Turning profitable
Expansion of ImprimisRx compounding services and market penetration in ophthalmology
Value
High premium - requires strong execution
Momentum
Hot
+21.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HROW right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 11, 2026
Reported EPS of -$0.74 vs -$0.43 consensus (-72.1% surprise). Revenue of $44.2M vs $52.4M expected (-15.7%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-72.1%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+84%
+38%
+30%
+45%
+33%
-8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$48.9M
$49.3M
$66.8M
$47.8M
$63.7M
$71.6M
$89.1M
$44.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-62.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$88.00
▲ +105.9% vs $42.74
Latest: Cantor Fitzgerald · $88.00 · May 13, 2026
1 analyst covering
vs Industry
How HROW stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related